| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 136.000 +5.15% on 12/13/21 | | 162.000 -11.73% on 01/07/22 | +4.000 (+2.88%) since 12/10/21 |
| 3-Month | 135.000 +5.93% on 12/09/21 | | 184.000 -22.28% on 11/05/21 | -37.500 (-20.78%) since 10/08/21 |
| 52-Week | 135.000 +5.93% on 12/09/21 | | 230.000 -37.83% on 03/16/21 | -52.000 (-26.67%) since 01/08/21 |
Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management of Acromegaly patients...
Amryt Pharma plc - Key Dates for AIM Delisting DUBLIN, Ireland, and Boston MA, January 6, 2022, Amryt Pharma plc (Nasdaq: AMYT, AIM: AMYT) (“Amryt” or the...
The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients ...
Total Voting Rights DUBLIN, Ireland, and Boston MA, January 4, 2022, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical...
Total Voting Rights DUBLIN, Ireland, and Boston MA, December 1, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical...
Amryt Pharma plc Director/PDMR Shareholding The following notification is made in accordance with the requirements of the EU Market Abuse Regulation (as...
Amryt Provides Update on Regulatory Review Process for Oleogel-S10 FDA PDUFA goal date extended by three months to February 28, 2022 EMA CHMP opinion now...
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 WHICH FORMS PART OF DOMESTIC...
Amryt Reports Strong Q3 2021 Results 14.6% YoY revenue growth in Q3 to $56.5M 21.5% growth in metreleptin revenues YoY to $36.3M in Q3; 51.6% growth YoY...
Amryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3 DUBLIN, Ireland, and Boston MA, October 20, 2021, Amryt (Nasdaq:...
| 3rd Resistance Point | 163.000 |
| 2nd Resistance Point | 159.000 |
| 1st Resistance Point | 151.000 |
| Last Price | 143.000 |
| 1st Support Level | 139.000 |
| 2nd Support Level | 135.000 |
| 3rd Support Level | 127.000 |
| 52-Week High | 230.000 |
| Fibonacci 61.8% | 193.710 |
| Fibonacci 50% | 182.500 |
| Fibonacci 38.2% | 171.290 |
| Last Price | 143.000 |
| 52-Week Low | 135.000 |